Compounds > amifampridine
Page last updated: 2024-11-08

amifampridine and ALS - Amyotrophic Lateral Sclerosis

amifampridine has been researched along with ALS - Amyotrophic Lateral Sclerosis in 2 studies

Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aisen, ML2
Sevilla, D2
Gibson, G1
Kutt, H1
Blau, A1
Edelstein, L2
Hatch, J1
Blass, J2

Trials

1 trial available for amifampridine and ALS - Amyotrophic Lateral Sclerosis

ArticleYear
A double-blind placebo-controlled study of 3,4-diaminopyridine in amytrophic lateral sclerosis patients on a rehabilitation unit.
    Journal of the neurological sciences, 1996, Volume: 138, Issue:1-2

    Topics: 4-Aminopyridine; Administration, Oral; Aged; Amifampridine; Amyotrophic Lateral Sclerosis; Cross-Ove

1996

Other Studies

1 other study available for amifampridine and ALS - Amyotrophic Lateral Sclerosis

ArticleYear
3,4-diaminopyridine as a treatment for amyotrophic lateral sclerosis.
    Journal of the neurological sciences, 1995, Volume: 129, Issue:1

    Topics: 4-Aminopyridine; Affect; Aged; Amifampridine; Amyotrophic Lateral Sclerosis; Cognition; Female; Huma

1995